Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03417154 · ClinicalTrials.gov registry record · Phase 2
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03417154 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 12 participants.
The verdict
NCT03417154, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a phase II trial of nivolumab and low dose cyclophosphamide (CTX) when given in combination to patients with relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS) who are not eligible for or decline hematopoietic stem cell transplant. It includes a randomized pilot sub-study during stage 1.
Interventions
- DRUG Nivolumab
- DRUG Low dose Cyclophosphamide (CTX) Daily
- DRUG Low dose Cyclophosphamide (CTX) Every 7 Days
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-08-13 |
| Est. Completion | 2022-01-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03417154
The ClinicalTrials.gov registry entry for NCT03417154 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03417154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03417154 about?
NCT03417154 is a clinical study titled "Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS". This is a phase II trial of nivolumab and low dose cyclophosphamide (CTX) when given in combination to patients with relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS) who are not eligible for or decline hematopoietic stem cell transplant. It includes a r...
What is the current status of trial NCT03417154?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2018-08-13. Estimated completion is 2022-01-25.
What interventions are being tested in trial NCT03417154?
The interventions under investigation include: Nivolumab (DRUG), Low dose Cyclophosphamide (CTX) Daily (DRUG), Low dose Cyclophosphamide (CTX) Every 7 Days (DRUG).
Who is sponsoring clinical trial NCT03417154?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.